Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — H1 FY24 Earnings Presentation
11 slides from Jagsonpal Pharmaceuticals's earnings presentation, Nov 3, 2023
Slide 1: Q2 & H1FY24 Earnings Presentation
Jagsonpal Pharmaceuticals Limited Q2 & H1FY24 Earnings Presentation November 03, 2023
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 3: Q2 & H1FY24 Performance
Q2 & H1FY24 Performance
Slide 4: Management Commentary
Management Commentary “We had a satisfactory outcome for the period, as the performance should be seen in the context of challenging external operating environment with slowing industry coupled with internal challenges in our flagship products - hyper competition with 75+ competitors in Divatrone® (
Slide 5: Financial Performance
Financial Performance H1 FY24 Update o Sales decline by 2.6% to ₹ 118.0 Crores o Gross Margins improve by 430 bps to 63.4% o Operational EBITDA improves by 17.6% to ₹ 25.4 Crores, margins at 21.5% - Improves by 360 bps o PAT improves by 12.8% to ₹ 15.0 Crores Q2 FY24 Update o Sales decline by 4.5% t
Slide 6: Business Update
Business Update Strong performance in focus molecules (Source: IQVIA) • Divatrone +24%, Indocap +20%, Endoreg +27%, Maintane +5%, Metadec +5% Strategic moderation in Dydrogesterone • Hypercompetition impacting internal growth, ProRetro discontinued Counterfeit Indomethacin product availability • Cou
Slide 7: Key Brands Progression (Source: IQVIA)
Key Brands Progression (Source: IQVIA) All values in ₹ Crores Company Market Brand MAT Sep’23 MAT Sep’22 Gr % MAT Sep’23 MAT Sep’22 Gr % Indocap/ SR 35.3 42.2 20% 48.9 55.9 14% Maintane Injection 36.8 38.6 5% 146.7 154.0 5% Divatrone/ ProRetro 30.1 37.4 24% 828.8 1,102.2 33% Metadec 31.9 33.6 5% 139
Slide 8: Financial Performance
Financial Performance
Slide 9: Profit and Loss Statement
Profit and Loss Statement All values in ₹ Mn Q2 FY 24 Q1 FY 24 Q2 FY 23 H1 FY24 H1 FY23 Particulars (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Revenue From Operations 578 602 605 1,180 1,211 Material Consumption -209 -223 -213 -432 -475 Gross Margin 369 379 393 748 737 % 63.8% 62.9%
Slide 10: Key Balance sheet Items
Key Balance sheet Items All values in ₹ Mn As at As at Particulars Movements 30 Sep 23 30 Jun 23 Shareholders Funds 1694 1706 -11 *Tangible Assets 11 182 -171 *Assets Held for Sale 172 0 172 Cash & Cash Equivalents 1243 1245 -2 Investments 11 11 0 Other Non-Current Assets (Net) 16 13 3 Net Working C
Slide 11: Thank You
Thank You Registered Office: T-210 J, Shahpur Jat New Delhi - 110 049 Corporate Office: Nimai Tower, 3rd Floor, Plot No: 412-415, Phase – IV, Udyog Vihar, Gurugram, Haryana - 122015 Tel. : 0124-4406710 E-mail : info@jagsonpal.com Website : www.jagsonpal.com CIN: L74899DL1978PLC009181
Jagsonpal Pharmaceuticals — H1 FY24 Earnings Presentation on 6ix